Table 4.
Modified functions and diseases obtained by differentially methylated genes after exposure to Covid-19 infection during pregnancy.
| Modified diseases and functions | Range of P-values for genes involved | Number of genes involved |
|---|---|---|
| Cancer | 3.98E-07-3.9E-02 | 138 |
| Organismal Injury and Abnormalities | 3.98E-07-3.9E-02 | 140 |
| Dermatological Diseases and Conditions | 9.24E-06-1.97E-02 | 108 |
| Gastrointestinal Disease | 2.82E-05-3.72E-02 | 128 |
| Cell Morphology | 1.3E-04-3.9E-02 | 17 |
| Hepatic System Disease | 1.8E-04-1.97E-02 | 83 |
| Reproductive System Disease | 3.27E-04-3.9E-02 | 95 |
| Cellular Development | 4.28E-04-3.83E-02 | 24 |
| Connective Tissue Development and Function | 4.28E-04-3.9E-02 | 10 |
| Tissue Morphology | 4.28E-04-3.9E-02 | 15 |
| Endocrine System Disorders | 5.23E-04-3.9E-02 | 118 |
| Embryonic Development | 6.4E-04-3.26E-02 | 12 |
| Organismal Development | 6.4E-04-3.9E-02 | 17 |
| Cellular Growth and Proliferation | 7.14E-04-3.9E-02 | 24 |
| Nervous System Development and Function | 7.14E-04-3.83E-02 | 9 |
| Neurological Disease | 8.91E-04-3.9E-02 | 92 |
| Developmental Disorder | 1.03E-03-3.9E-02 | 29 |
| Renal and Urological Disease | 1.03E-03-3.63E-02 | 14 |
| Cardiovascular Disease | 1.4E-03-2.36E-02 | 5 |
| Cell-To-Cell Signaling and Interaction | 1.91E-03-3.9E-02 | 16 |
| Hematological System Development and Function | 1.91E-03-3.9E-02 | 14 |
| Immunological Disease | 3.23E-03-3.61E-02 | 43 |
| Respiratory Disease | 5.78E-03-3.9E-02 | 63 |